BioXcel Therapeutics (BTAI) Capital Expenditures (2018 - 2022)
BioXcel Therapeutics (BTAI) posted quarterly Capital Expenditures of $19000.0 for Q2 2022, down 81.0% year-over-year from $100000.0 in Q2 2021, and down 84.17% quarter-over-quarter from $120000.0 in Q1 2022.
BioXcel Therapeutics (BTAI) Capital Expenditures (2018 - 2022) Analysis & Trends
BioXcel Therapeutics' Capital Expenditures history runs 5 years deep, the most recent figure standing at $19000.0 for Q2 2022.
- In Q2 2022, Capital Expenditures fell 81.0% year-over-year to $19000.0; the TTM figure through Sep 2023 stood at $19000.0 (up 106.99% YoY), while the FY2023 annual figure was $20000.0, down 85.61% from the prior year.
- Capital Expenditures for Q2 2022 stood at $19000.0, down from $120000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $600000.0 in Q1 2019, with the low at -$411000.0 in Q4 2021.
- The 5-year median for Capital Expenditures is $52500.0 (2018), against an average of $97937.5.
- The sharpest annual moves came in 2020 and 2021: Capital Expenditures soared 13400.0% in 2020, then sank 252.22% in 2021.
- BioXcel Therapeutics' Capital Expenditures stood at $158000.0 in 2018, then sank by 98.73% to $2000.0 in 2019, then jumped by 13400.0% to $270000.0 in 2020, then tumbled by 252.22% to -$411000.0 in 2021, then jumped by 104.62% to $19000.0 in 2022.
- Business Quant data shows BTAI's Capital Expenditures at $19000.0 in Q2 2022, $120000.0 in Q1 2022, and -$411000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 104.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 117.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | -337.60 Mn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 108.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 52.80 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 7.80 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 33.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | BioXcel Therapeutics | 24.24 Mn | 24.24 Mn | 160,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 19,000.00 |
| Jun 30, 2022 | 19,000.00 |
| Mar 31, 2022 | 120,000.00 |
| Mar 31, 2022 | 120,000.00 |
| Dec 31, 2021 | -411,000.00 |
| Dec 31, 2021 | -411,000.00 |
| Sep 30, 2021 | 17,000.00 |
| Sep 30, 2021 | 17,000.00 |
| Jun 30, 2021 | 100,000.00 |
| Jun 30, 2021 | 100,000.00 |
| Mar 31, 2021 | 316,000.00 |
| Mar 31, 2021 | 316,000.00 |
| Dec 31, 2020 | 270,000.00 |
| Dec 31, 2020 | 270,000.00 |
| Sep 30, 2020 | -5,000.00 |
| Sep 30, 2020 | -5,000.00 |
| Jun 30, 2020 | 35,000.00 |
| Jun 30, 2020 | 35,000.00 |
| Mar 31, 2020 | 16,000.00 |
| Mar 31, 2020 | 16,000.00 |